Aberdeen Group’s Axsome Therapeutics AXSM Stock Holding History

Aberdeen Group’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.1M	Sell	78,236 -71,452	-48%	-$15.5M	0.03%	457
2026 Q1	$25.3M	Buy	149,688 +52,275	+54%	+$9.03M	0.04%	352
2025 Q4	$17.8M	Buy	97,413 +2,765	+3%	+$386K	0.03%	468
2025 Q3	$11.5M	Buy	94,648 +12,732	+16%	+$1.43M	0.02%	585
2025 Q2	$8.55M	Buy	81,916 +17,962	+28%	+$1.9M	0.01%	631
2025 Q1	$7.46M	Sell	63,954 -8,225	-11%	-$937K	0.01%	628
2024 Q4	$6.11M	Buy	72,179 +61,131	+553%	+$5.62M	0.01%	613
2024 Q3	$993K	Sell	11,048 -28,627	-72%	-$2.5M	﹤0.01%	810
2024 Q2	$3.19M	Buy	+39,675	New	+$2.94M	0.01%	700

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Aberdeen Group's AXSM Position: Q2 2026 in Review

Aberdeen Group reduced its Axsome Therapeutics (AXSM) stake by 48% in Q2 2026, selling an estimated $15.5M and leaving 78,236 shares worth $19.1M. The position accounts for 0.03% of the portfolio, ranked #457.

Aberdeen Group first reported a position in AXSM in Q2 2024 and has held it in 9 quarters since. The position peaked at $25.3M in Q1 2026. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Aberdeen Group held 78,236 shares of Axsome Therapeutics worth $19.1M as of Q2 2026.
Aberdeen Group sold 71,452 Axsome Therapeutics shares in Q2 2026, an estimated $15.5M.
Axsome Therapeutics made up 0.03% of Aberdeen Group's portfolio in Q2 2026, its #457 holding.
Aberdeen Group first reported a position in Axsome Therapeutics in Q2 2024 and has held it in 9 quarters since.
Aberdeen Group's Axsome Therapeutics position peaked at $25.3M in Q1 2026.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.